Discovery and Evaluation of Pyrazolo[3,4-d]pyridazinone as a Potent and Orally Active Irreversible BTK Inhibitor

Abstract

The identification and lead optimization of a series of pyrazolo[3,4-d]pyridazinone derivatives are described as a novel class of potent irreversible BTK inhibitors, resulting in the discovery of compound 8. Compound 8 exhibited high potency against BTK kinase and acceptable PK profile. Furthermore, compound 8 demonstrated significant in vivo efficacy in a mouse-collagen-induced arthritis (CIA) model.

References

Page 1

	Year	Citations
Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia John C. Byrd, Richard R. Furman, Steven Coutré, New England Journal of Medicine	2013	2.2K
Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell Lymphoma Michael Wang, Simon Rule, Peter Martin, New England Journal of Medicine	2013	1.7K
The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy Lee Honigberg, Ashley M. Smith, Mint Sirisawad, Proceedings of the National Academy of Sciences ImmunologyPathologyImmunologic MechanismImmunotherapyHematological Malignancy	2010	1.5K
The gene involved in X-linked agammaglobulinaemia is a member of the src family of protein-tyrosine kinases David Vetrie, Igor Vořechovský, Paschalis Sideras, Nature Protein FunctionSignal TransductionMolecular PhysiologyReceptor Tyrosine KinaseGenetics	1993	1.5K
Deficient expression of a B cell cytoplasmic tyrosine kinase in human X-linked agammaglobulinemia Satoshi Tsukada, Douglas C. Saffran, David J. Rawlings, Cell Autoimmune DiseaseReceptor Tyrosine KinaseMalignant Blood DisorderDeficient ExpressionHematology	1993	1.3K
Ibrutinib in Previously Treated Waldenström’s Macroglobulinemia Steven P. Treon, Christina Tripsas, Kirsten Meid, New England Journal of Medicine	2015	913
Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia John C. Byrd, Bonnie K. Harrington, Susan O’Brien, New England Journal of Medicine	2015	878
Discovery of Selective Irreversible Inhibitors for Bruton’s Tyrosine Kinase Zhengying Pan, Heleen Scheerens, Shyr‐Jiann Li, ChemMedChem Rheumatoid DisorderMolecular PharmacologyMedicinal ChemistryRheumatologyStructural Bioinformatics Approach	2006	669
Specific Btk inhibition suppresses B cell– and myeloid cell–mediated arthritis Julie A. Di Paolo, Tao Huang, Mercedesz Balázs, Nature Chemical Biology InflammationRheumatologyRheumatoid DisorderAutoimmune DiseaseImmune Cell Development	2010	328
Discovery of GDC-0853: A Potent, Selective, and Noncovalent Bruton’s Tyrosine Kinase Inhibitor in Early Clinical Development James J. Crawford, Adam R. Johnson, Dinah Misner, Journal of Medicinal Chemistry Tyrosine KinaseImmunologyBiological TherapyPharmacotherapyImmunotherapeutics	2018	240

Page 1